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Abstract  
Purpose:   The aim of this research therefore is to explore the causes of drug shortages within the 
pharmaceutical supply chain and assess the adopted mitigation strategies. 
Research Approach: The study is carried out from an inductive perspective where we seek to 
understand the phenomenon by a detailed review of extant literature followed by a series of semi-
structured interviews with first tier consumers within a case study framework. The respondents were 
chosen using purposive sampling as those best to comment on the phenomenon under scrutiny. Data 
was analysed using thematic analysis, where a dual focus was adopted; 1) the preliminary focus was on 
the identification of system themes (where the system was impacted and the responds e.g. complexity, 
disruptions and product alternatives) and 2) the secondary focus was the impact on the patient as 
system recipient and product user   (where themes such as stress, anxiety, and adverse drug reactions 
emerged).  
Findings and Originality: The analysis show that drug shortages within the pharmaceutical supply chain 
in the UK occur as a result of stringent regulatory frameworks, faults in the manufacturing processes, 
lack of Active Pharmaceutical Ingredients, monopolistic wholesaler markets; lack of information 
dissemination, offshore trading and price manipulations for profit.  The impact on the consumers is 
reported to be extensive and can endure long after the disruptive event occurs. The findings indicate 
that existing recovery strategies are however cumbersome, add complexity to the supply chain and in 
extreme cases facilitate the infiltration of counterfeits. The study is innovative as it explores disruptive 
events and associated recovery strategies which have not been adequately addressed in supply chain 
management studies to date. 
Research Impact: This research contributes to existing literature by extending discussions on supply 
chain disruptions within a dynamic supply chain whilst focusing on product service supply chain recovery 
strategies and mechanisms.  
Practical Impact: This study provides Operations/Supply Chain Managers and Pharmaceutical companies 
and professionals with strategies that can be adopted can adopt in reducing and recovering in a more 
resilient manner to disruptive events. This thus presents the bedrock for resilient practice and systems 
design and development, thus reducing system vulnerability and ultimately leading to improved product 
availability and patient care.  
Introduction  
This study examines the causes of drug shortages as a disruptive event in the UK pharmaceutical supply 
chain. More specifically, the study seeks to explore why the pharmaceutical supply chain are susceptible 
to drug shortages. This is pertinent because, drug shortages are defined as a supply issue that affects 
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how the pharmacy prepares or dispenses a drug product of influences patients care (Panels, 2015), and 
has become a global phenomenon which has risen significantly over the last decade (Pauwels et al., 
2015). For instance, a survey on drug shortages by European Association of Hospital Pharmacists (2015) 
revealed that 99% of pharmacists in European hospitals experienced drug shortages in the year under 
review.  Drug shortages  is potentially detrimental to the patient as well as members of the supply 
chains as it can harm treatments, delay medical procedures, and result in medication errors (De Weerdt 
et al., 2017). This study therefore seeks to contribute to existing supply chain literature by examining the 
weaknesses that make the supply chain susceptible to drug shortages. This section provides the 
background to the study; the next section explores concepts related to understanding drug shortages 
within the supply chain literature, while section three will present the methodological approach. The 
study concludes in section five with a conclusion and recommendation for best practice. 
Literature Review 
Supply chain disruptions which are events that disrupt the normal flow of goods and services within a 
supply chain have been reported to have adverse effects on the financial and operational performance 
of the firm (Schimdt and Raman, 2012; Urciuoli et al., 2014; Thekdi and Sarvos, 2016). This 
notwithstanding, the research on this topic has received limited empirical attention (Bode et al. 2011; 
Simangunsong et al., 2012). It is also purported that existing literature tends to examine disruptive 
events as homogenous, in spite of the fact that they have varying causes and effects as well different 
mitigation strategies (DuHadway et al., 2017). Supply chain disruptions can therefore be classified based 
on the sources of disruptions which could be exogenous or endogenous (Hendricks et al., 2009; Urciouli 
et al., 2014; Gunasekarean et al. 2015); action of the disruption as intentional or unintentional (Marley 
et al., 2014); as well as impact of the disruption as dynamic or stable (Saghafian and Van Oyen, 2016). 
Similarly, supply chain complexity (Wagner and Bode, 2016), supply chain structure (Craghead et al., 
2007), the characteristics of the supply chain (Wagner and Bode, 2009), global sourcing as well as 
outsourcing (Christopher and Holweg 2011) have been suggested as elements that increase supply 
chains vulnerabilities to various disturbances (Craighead et al., 2007; Ellis et al., 2011; Chopra and Sodhi 
2014) and economic factors such as wage inflation in lower cost countries (Wagner and Neshat 2012). 
For instance, the  Japaneese earthquake and Tsunami in 2011, which disrupted the  supply of glycine (an 
ingredient for solid-dosage products and the gelatine used in soft gel capsules -(Miller 2011))- in some 
pharmaceutical supply chains exposed these supply chains to various risk as a result of the complex 
multi-layered supply chain as well as outsourcing.  
However, empirical evidence exploring vulnerabilities of the pharmaceutical supply chain is limited. For 
instance, -Breen (2008) explored the nature and prevalence of risk in the pharmaceutical supply chain 
and identified 35 risks the supply chain was exposed to. Also, Quadri et al., (2015) explored the causes of 
antibacterial shortages from 2001 and 2013 in the US, using the Utah database of drug information, they 
found that a total of 148 drugs were short in supply over a 13 year period. This study however fails to 
explore why these drug shortages occurred and how they were being tackled. Similarly, Pauwels et 
al.,(2015), studied the characteristics, effect, causes and management of drug shortages of hospital 
pharmacies in Europe and find that drug shortages  were caused parallel trading, tendering and 
manufacturing problems. This study however examined only hospital pharmacists and explored it from a 
clinical perspective. In view of this, there is need to examine in detail why the pharmaceutical supply 
chains are susceptible to drug shortage, from an operations management perspective. As such, this 
study hopes to answer the following questions: Why is the pharmaceutical supply chain exposed to 
dynamic disruptions like drug shortages? How do pharmaceutical supply chains mitigate the impact of 
these disruptions? 
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Research Strategy and Design  
The case study approach which is a rigorous and well established research method was chosen as the 
research strategy (Yin, 2013). The case study was considered appropriate as it presents an avenue for 
the researcher to investigate a phenomenon in a real life setting as well as suitable for research areas 
with limited pre-existing theories (Gibbert, et al., 2008).  
Data for this study was gathered in two separate stages, where multiple data sources and different data 
collection methods was employed. The first stage began with a review of literature using the systematic 
literature review approach, to understand the underlying constructs of supply chain disruption as well as 
to effectively classify the phenomenon under study. The next stage involved the selection of the case 
study. The convenience sampling technique was the criteria for selecting the case study.  An invitation to 
participate in the research was circulated and interviewees who positively replied to the invitation were 
used.  Multiple case studies were employed which provided depth as well as breadth to the study ( Yin, 
2013).  The first tier consumers which are pharmacists, were specifically selected for this study , as the 
study draws upon the definition of drug shortages by Panel(2009)-A supply issue that affects how a 
pharmacy prepares or dispenses a drug or influences patients care-.’ This suggests that the bane of drug 
shortages rests on pharmacist within the pharmaceutical supply chain.                                      
Prior to the interview, the participants were sent an interview protocol and a leaflet which provided a 
brief of the research. In line with case study guidelines highlighted by Yin (2013),   the first two 
interviews were conducted on the participants’ premises where each interview lasted between 30-45 
mins.  However whilst analysing these interviews, the need to explore other categories of first tier 
consumers arose, as such the snowballing technique was employed to access hospital and online 
pharmacists. As such: the total numbers of participants were two community pharmacists, 1 online 
pharmacist and two hospital pharmacists. The participants however choose to remain anonymous with 
regards to the study. The interviews were audio-recorded after receiving consent from the interviewee 
and then transcribed manually following the 24 hours recommendation as highlighted by (Blackhurst et 
al., 2011). The transcripts were coded and analysed using a software package called Nvivo.  
Analysis of Data  
In order to deliver to the study aim, during the interview, participants were asked the following: what is 
your understanding of drug shortages and why do you think drug shortages occur. The findings are 
described in accordance with existing literature and matched with excerpts from the transcripts. Table 2 
below presents a summary of the analysis of the study.  
Table 2 Causes of Drug Shortages  
Emerging themes Definition In Literature  Excerpts from Interviews 




The manufacturing process of a 
pharmaceutical which is tagged as 
cumbersome is another highlighted 
factor that exposes the supply 
chain to drug shortages. These 
manufacturing processes may 
range from the failure of the 
product to reach the desired 
quality as stipulated by the 
regulating bodies, or the lack of 
raw materials which most times is 




Hospital Pharm. 1 
‘A product recall can cause a drug shortage and this can happen for 
instance if the firm discovers that a batch of drugs that had gone out, did 
not meet the quality requirements‘. 
 
Hospital Pharm. 2 
‘The MHRA regulates the quality of drugs produced for consumption in the 
United Kingdom for the right grade and the right ingredients, if a firm fails 
the quality check in the production of raw materials, they will have to 
reorder it, sometime these raw materials come from different parts of the 
world which may take weeks to get. These create a backlog in the 
production processes and hence cause drug shortages’. 
Community Pharm. 1 
‘A break down in the manufacturing plant or something as trivial as a 
change in packaging can upset the whole system. Like with the Glucopen 
recall where they could not source for the active ingredients’. 
Managerial Practices The managerial practices of the 
firm also weaken the system which 
in turn makes it impossible for the 
system to resist drug shortages 
when they occur making it 
vulnerable to various risks 
(Blackhurst et al, 2011). This is 
evidenced from the data, For 
instance, an informant explained 
that some manufacturers had to 
adopt the managerial practice of 
rationing drugs supplied to 
wholesalers and pharmacists, to 
curb wholesalers and some 
pharmacists who sold medicines 
abroad because they were more 
profitable. While this strategy was 
effective for a while, it however 
leads to drug shortages in the long 
run (Bogaert et al., 2015).  
 
Community Pharm.2 
‘We also have incidences of manufacturing firms rationing drugs we buy 
and supply the drugs based on a quota system. For instance last month we 
had to fight a manufacturer because our quota for a particular drug was 
zero and we had two patients on this drug which will cause a shortage. I 
think manufacturing firms decided to start selling drugs on quota system 
to curb the incidence of wholesalers or even some community pharmacists 
who were selling drugs abroad for profit’. 
Hospital  Pharm.1 
‘Manipulation of the market for profit, like what happened with pain 
killers-Codeine- a few years back, firms withheld products to create 
artificial scarcity, because they had forecasted a level of sales which had 
not been attained, they created artificial scarcity, increased the prices by 
about a couple of pennies and then re-introduced it back into the market 
when the agitation was high. Sometimes, artificial scarcity maybe because 
of the NHS price lists which makes profit margin quite narrows.’ 
Community Pharm.1 
‘Selling of drugs abroad for profit is one major cause of drug shortages. 
Some wholesalers and even community pharmacists who have licences to 
trade, will buy drugs at a cheaper rate from the manufacturers and sell 
overseas especially within the EU region for profit creating drug scarcity. 
Sometimes, these wholesalers will have to repurchase these drugs again 
from overseas as a result of the quota system introduced by the 
manufacturing firms’. 
Online Pharm. 1 
‘A whisper that a drug is going out of circulation may cause panic among 
pharmacists. Then we order about three months’ worth of the drugs, to 
save for the rainy day. This will cause the drug to become scarce in the 
market and then the prices will go up. Sometimes we get to sell to other 
community pharmacists for a gain’.  
Supply Chain 
Characteristics 
Supply chain characteristic which 
depicts buyer supplier relationship 
includes; supplier dependence and 
consumer dependence.  Supplier 
dependence is the degree to which 
a firm sources its inputs from a 
single supplier to alternative 
suppliers (Wagner and 
Neshat,2012; Peck, 2005). 
Community  Pharm. 2 
‘Let’s say  there is only one supplier that supplies a drug, and the supplier 
fails a quality check of raw materials, they may not be able to meet up 
production capacity  which will cause the drug to become scarce. This 
happened with the case of Lazoprizole several years back’. 
Community Pharm.1 
‘Usually manufacturing firms use historical records of patients and the 
consumption pattern of a particular drug to determine the quantity it will 
produce. Sometimes they do not forecast correctly, as the number of 
consumers may vary depending of change in lifestyle. Take for instance 
anti-depressant drugs’. 
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Supplier Selection  
 
Supplier selection refers to the 
process of selecting a supplier 
based on price negotiation and the 
ability to share in supply and 
demand risk (Chopra and Meindl, 
2007). 
 Hospital Pharm. 1 
‘Sometimes it may not necessarily be a drug shortage as it may be the 
hospital management board’s decision not to stock it on its formulary. For 
instance, I had a patient who came in yesterday and is taking lycionpril 
and hydrochrothyzine combination, we did not have it at the hospital, it 
was a local level decision not to stock the product’. 




The structure of the supply chain 
deals with the design of the chain, 
which can either be centralized or 
decentralized (Yang et al.,2015) 
Online Pharm. 1 
 ‘I think the way the supply chain in the pharmaceutical industry is 
designed makes it difficult to access drugs. I feel smaller firms are penny 
pinching as they really do not make any profits. What really is is that we 
have the manufacturers and three major wholesalers who own and control 
the biggest retail stores/community pharmacies. Although there are short 
liners (small wholesalers), they sell basically generic drugs. When a drug is 
in short supply at the retail level, the big retailers simply meet their 
wholesalers or the multiple company for while small retailers have to get 
the drugs at a more expensive rate.’  
Lack of Information 
sharing  
 
Information sharing is necessary for 
integrating a supply chain (SC). To 
achieve efficiency, members in a 
supply chain are expected to 
collaborate in managing material, 
information and financial flow(Bian 
et al., 2016;Riley et al.,2016) 
Community Pharm. 1 
‘In most cases, the manufacturing firms do not give reasons why we can’t 
have a drug. You may call them to find out but you really can’t get any 
information from them. Sometimes this information is required so we can 
explain to the patient better on why their drugs are unavailable. Also the 
firm should forewarn us in advance so we can be proactive because 
whispers may just lead to more shortages.’ 
Community Pharm. 2 
‘Your relationship in the market place is vital as lack of relationship will 
limit your information, increase the amount of shortages as well as lead to 
huge losses.’ 
 
4.2   Response of Drug Shortages to the Pharmaceutical Supply Chain 
The study also asked how the firms managed drug shortages. The responses show that drug shortages 
have adverse effect on the supply chain as well on the patients. For instance, the study shows that trust 
between members of the supply chain are eroded when drug shortages occur. Sometimes this 
severance in trust may be between the patient and the pharmacists, the pharmacists and the wholesaler 
or even the manufacturer. 
Table 3 Impact of Drug Shortages on the Pharmaceutical Supply Chain 
Impact within the PSC  Excerpts from Transcript 
Eroded Trust This is consistent with extant studies arguing 
that, under high trust conditions, the proclivity of economic 
actors to be opportunistic decreases, whereas under low trust 
conditions economic actors are more likely to behave 
opportunistically. 
Community Pharm.1 
‘Sometimes when we receive a whisper that a drug is going 
out of circulation may cause panic among pharmacists. Then 
we order about three months’ worth of the drugs, to save for 
the rainy day. This will cause the drug to become scarce in the 
market and then the prices will go up. Sometimes we get to 
sell to other community pharmacists for a gain’. 
‘If we decide to offer alternatives to the patients, some of 
them react psychologically’. I had a patient who had tried 
every form of anti-depressant and she reacted to them in 
various ways. Then she came to the pharmacy one day to pick 
up her drugs-the only combination that worked for her and I 
had to inform her that her drugs were unavailable. She 
actually went into a fit; I spent the best part of that day trying 
to reassure her that her drugs will be with her soon. Calling 
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Another effect of drug shortages is that the patients are also exposed to safety risks and financial risk as 
the patient may seek for alternative drugs outside the supply chain.  Also, by seeking alternatives 
outside the supply chain, patients may knowingly or unknowingly purchase counterfeits.  Consistent use 
of the alternative drug may also affect forecast of the alternatives and lead to the shortage of the 
alternative drug as well. Drug shortages can also delay patient’s treatments as the source for 
appropriate alternatives continues which can lead to adverse drug reaction and complications.  
Sometimes, patients may react to drug shortages psychologically which may lead to several 
complications. The pharmacists are also stressed from having to explain to the patients the need for an 
alternative as well as seeking for the alternative.  The need to call the GP to re-prescribe further 
complicates the supply chain and lengthens patients’ delivery processes. 
The findings also reported that mitigation strategies employed by pharmacists were the use of 
alternatives and sometimes stock piling if notification of a shortage was provided in a timely fashion. 
The use of alternative however is cumbersome as there is the need to understand the patients profile in 
order to come up with suitable alternative. The respondents felt that at times the medicines ‘matching’ 
process can fail, leading to a failure in the system.  This implies that when a whisper is acted upon and it 
is not necessarily true, firms may not trust the information and resent the operational rework that they 
have had to undertake. Similarly, if firms get to know the reason for the drug shortage, like unethical 
hoarding of a product or parallel trading, trust is destroyed. 
Conclusion 
The aim of this research was to examine why drug shortages occurred within the pharmaceutical supply 
chain as well as assess the adopted mitigation strategies. The study was carried out from an inductive 
perspective where semi-structured interviews with first tier consumers within a case study framework 
was carried and analysed using thematic analysis. The findings show that the pharmaceutical supply 
chain in the UK is vulnerable to drug shortages as a result of managerial practices, manufacturing 
processes, supply chain characteristics, supplier selection and lack of information sharing. The study also 
the GP to re prescribe an alternative was also a hassle’ 
Exposure to Risk (Financial, Security, Counterfeiting) Community Pharm. 1 
‘When a patient comes to collect his prescription and its 
unavailable, after we have tried our possible best to get more 
stock and we can’t seem to be making a headway, we ask the 
patient to go out and look for the drug’ 
Community Pharm. 2 
 ‘Although we have never seen a counterfeit in our pharmacy, I 
have had a patient who went overseas on holiday and could 
not travel with his regularly drug. When he got back he had 
purchased a drug and asked me to confirm its authenticity’ 
 
Supply Chain Complexity  Community  Pharm.  2 
‘Delay in patient’s treatment occurs when we the pharmacist 
will have to call the receptionist to inform the GP that the 
prescribed medicines are unavailable. The GP has to go 
through the patient’s medical history to understand the 
medical situation, before re prescribing an alternative. This 
process may take a couple of hours or even days and we as 
community pharmacists have no power to prescribe 
alternatives’. 
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finds that these vulnerabilities expose the supply chain to financial, operational and safety risks.  
Similarly, the supply chain becomes more complex as a result of the adopted mitigation strategies and in 
some cases creates drug shortages in alternative supply chains. 
Further areas for research should seek to understand these mitigation strategies and identify resilient 
strategies that will minimize the supply chains systems response negatively. 
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